<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02018627</url>
  </required_header>
  <id_info>
    <org_study_id>2013P002549</org_study_id>
    <nct_id>NCT02018627</nct_id>
  </id_info>
  <brief_title>Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon</brief_title>
  <official_title>Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Steven J. Russell, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the hypothesis that micro-doses of Xerisol Glucagon (Xeris
      Pharmaceuticals) will be non-inferior by pharmacokinetic and pharmacodynamic criteria vs.
      micro-doses of Glucagon for Injection (Eli Lilly).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will test the hypothesis that micro-doses of a new formulation of stable glucagon,
      Xerisol Glucagon (Xeris Pharmaceuticals), will be non-inferior by pharmacokinetic and
      pharmacodynamic criteria vs. micro-doses of a freshly reconstituted formulation of glucagon
      that has poor stability in solution, Glucagon for Injection (Eli Lilly).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">August 2, 2018</completion_date>
  <primary_completion_date type="Actual">August 2, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>every 2 minutes for 1 hour post-dose of each glucagon</time_frame>
    <description>tmax for Xeris vs. Lilly (non-inferiority)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AOCGIR</measure>
    <time_frame>every 2 minutes for 1 hour post-dose of each glucagon</time_frame>
    <description>Area over the curve for glucose infusion rate in the hour following administration (AOCGIR) for Xeris vs. Lilly (non-inferiority)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GIRmin</measure>
    <time_frame>every 2 minutes for 1 hour post-dose of each glucagon</time_frame>
    <description>Minimal glucose infusion rate (GIRmin) for Xeris vs. Lilly (non-inferiority)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t½Max</measure>
    <time_frame>every 2 minutes for 1 hour post-dose of each glucagon</time_frame>
    <description>Glucagon t½max for Xeris vs. Lilly (non-inferiority)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Injection Pain</measure>
    <time_frame>immediately after injection</time_frame>
    <description>Quantitation of adverse events related to glucagon injection for Xeris vs. Lilly:
-average Injection pain on a 10 cm standard VAS: 0 = no pain, 10 = worst imaginable pain reported immediately after injection of glucagon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Injection Site Erythema</measure>
    <time_frame>within 1 hour of injection</time_frame>
    <description>Quantitation of adverse events related to glucagon injection for Xeris vs. Lilly:
-Injection site erythema or other local reaction, maximum diameter within 1 hour of injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal Nausea</measure>
    <time_frame>within 1 hour of injection</time_frame>
    <description>Quantitation of adverse events related to glucagon injection for Xeris vs. Lilly:
-Maximal nausea within 1 hour of injection on a 10 cm VAS: no nausea = 0, vomiting = 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermal Response (Draize Scale for Erythema and Eschar Formation)</measure>
    <time_frame>within 1 hour of injection</time_frame>
    <description>Average grade on the erythema and eschar formation portion of the Draize scale for dermal response (0 being the lowest, 4 being the highest)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermal Response (Draize Scale Grade for Edema Formation)</measure>
    <time_frame>within 1 hour of injection</time_frame>
    <description>Average grade on the edema formation portion of the Draize scale for dermal response (0 being the lowest, 4 being the highest)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Xeris glucagon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Xeris glucagon 50 micrograms, subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lilly glucagon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lilly glucagon 30 micrograms, subcutaneous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xeris glucagon</intervention_name>
    <description>The subject is given an injection of xeris glucagon</description>
    <arm_group_label>Xeris glucagon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lilly glucagon</intervention_name>
    <description>The subject is given an injection of lilly glucagon</description>
    <arm_group_label>Lilly glucagon</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 21 to 80 years old with type 1 diabetes for at least one year.

          -  Diabetes managed using an insulin infusion pump using rapid-acting insulin such as
             insulin aspart (NovoLog), insulin lispro (Humalog), and insulin glulisine (Apidra) for
             at least one week prior to enrollment.

        Exclusion Criteria:

          -  Unable to provide informed consent.

          -  Unable to comply with study procedures.

          -  Current participation in another diabetes-related clinical trial that, in the judgment
             of the principle investigator, will compromise the results of the clamp study or the
             safety of the subject.

          -  Pregnancy (positive urine HCG), breast feeding, plan to become pregnant in the
             immediate future, or sexually active without use of contraception.

          -  End stage renal disease on dialysis (hemodialysis or peritoneal dialysis).

          -  Hemoglobin &lt; 11.5 gm/dl.

          -  History of pheochromocytoma. Fractionated metanephrines will be tested in patients
             with history increasing the risk for a catecholamine secreting tumor (paroxysms of
             tachycardia, pallor, or headache; personal or family history of MEN 2A, MEN 2B,
             neurofibromatosis, or von Hippel-Lindau disease; episodic or treatment of refractory
             hypertension, defined as requiring 4 or more medications to achieve normotension).

          -  History of adverse reaction to glucagon (including allergy) besides nausea, vomiting,
             or headache.

          -  Inadequate venous access as determined by study nurse or physician at time of
             screening.

          -  Liver failure or cirrhosis.

          -  Any other factors that, in the judgment of the principal investigator, would interfere
             with the safe completion of the study procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven J Russell, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>December 16, 2013</study_first_submitted>
  <study_first_submitted_qc>December 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2013</study_first_posted>
  <results_first_submitted>August 29, 2019</results_first_submitted>
  <results_first_submitted_qc>September 17, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 8, 2019</results_first_posted>
  <last_update_submitted>September 17, 2019</last_update_submitted>
  <last_update_submitted_qc>September 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Steven J. Russell, MD, PhD</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>bionic pancreas</keyword>
  <keyword>artificial pancreas</keyword>
  <keyword>insulin</keyword>
  <keyword>glucagon</keyword>
  <keyword>clamp</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 22, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/27/NCT02018627/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>20 subjects were enrolled in this study. One was ineligible after enrollment. 4 were enrolled and eligible, but were not able to schedule their study visit. 2 participated in &quot;test run&quot; experiments as we adjusted glucagon doses to account for concentration differences. 13 subjects completed experiments using the same protocol.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Xeris Glucagon First, Then Lilly Glucagon</title>
          <description>Xeris glucagon 50 micrograms, subcutaneous injection then Lilly glucagon 30 micrograms, subcutaneous injection
Lilly glucagon: The subject is given an injection of lilly glucagon Xeris glucagon: The subject is given an injection of xeris glucagon</description>
        </group>
        <group group_id="P2">
          <title>Lilly Glucagon First, Then Xeris Glucagon</title>
          <description>Lilly glucagon 30 micrograms, subcutaneous injection then Xeris glucagon 50 micrograms, subcutaneous injection
Lilly glucagon: The subject is given an injection of lilly glucagon Xeris glucagon: The subject is given an injection of xeris glucagon</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Xeris Glucagon First, Then Lilly Glucagon</title>
          <description>Xeris glucagon 50 micrograms, subcutaneous injection, then Lilly glucagon 30 micrograms, subcutaneous injection
Xeris glucagon: The subject is given an injection of xeris glucagon Lilly glucagon: The subject is given an injection of lilly glucagon</description>
        </group>
        <group group_id="B2">
          <title>Lilly Glucagon First, Then Xeris Glucagon</title>
          <description>Lilly glucagon 30 micrograms, subcutaneous injection, then Xeris glucagon 50 micrograms, subcutaneous injection
Lilly glucagon: The subject is given an injection of lilly glucagon Xeris glucagon: The subject is given an injection of xeris glucagon</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.0" spread="11.8"/>
                    <measurement group_id="B2" value="45.6" spread="11.9"/>
                    <measurement group_id="B3" value="51.7" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin A1c</title>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.4" spread="1.3"/>
                    <measurement group_id="B2" value="7.0" spread="0.6"/>
                    <measurement group_id="B3" value="7.2" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Tmax</title>
        <description>tmax for Xeris vs. Lilly (non-inferiority)</description>
        <time_frame>every 2 minutes for 1 hour post-dose of each glucagon</time_frame>
        <population>13 subjects completed the study following a consistent protocol using the glucagon doses described in the arm/group description. 7 subjects were randomized to get Xeris glucagon first, 6 subjects were randomized to get Lilly glucagon first. All 13 subjects received both glucagon injections, and the data is reported for each drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Xeris Glucagon</title>
            <description>Xeris glucagon 50 micrograms, subcutaneous injection
Xeris glucagon: The subject is given an injection of xeris glucagon</description>
          </group>
          <group group_id="O2">
            <title>Lilly Glucagon</title>
            <description>Lilly glucagon 30 micrograms, subcutaneous injection
Lilly glucagon: The subject is given an injection of lilly glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax</title>
          <description>tmax for Xeris vs. Lilly (non-inferiority)</description>
          <population>13 subjects completed the study following a consistent protocol using the glucagon doses described in the arm/group description. 7 subjects were randomized to get Xeris glucagon first, 6 subjects were randomized to get Lilly glucagon first. All 13 subjects received both glucagon injections, and the data is reported for each drug.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.8" spread="9.3"/>
                    <measurement group_id="O2" value="15.7" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AOCGIR</title>
        <description>Area over the curve for glucose infusion rate in the hour following administration (AOCGIR) for Xeris vs. Lilly (non-inferiority)</description>
        <time_frame>every 2 minutes for 1 hour post-dose of each glucagon</time_frame>
        <population>13 subjects completed the study following a consistent protocol using the glucagon doses described in the arm/group description. 7 subjects were randomized to get Xeris glucagon first, 6 subjects were randomized to get Lilly glucagon first. All 13 subjects received both glucagon injections, and the data is reported for each drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Xeris Glucagon</title>
            <description>Xeris glucagon 50 micrograms, subcutaneous injection
Xeris glucagon: The subject is given an injection of xeris glucagon</description>
          </group>
          <group group_id="O2">
            <title>Lilly Glucagon</title>
            <description>Lilly glucagon 30 micrograms, subcutaneous injection
Lilly glucagon: The subject is given an injection of lilly glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>AOCGIR</title>
          <description>Area over the curve for glucose infusion rate in the hour following administration (AOCGIR) for Xeris vs. Lilly (non-inferiority)</description>
          <population>13 subjects completed the study following a consistent protocol using the glucagon doses described in the arm/group description. 7 subjects were randomized to get Xeris glucagon first, 6 subjects were randomized to get Lilly glucagon first. All 13 subjects received both glucagon injections, and the data is reported for each drug.</population>
          <units>mg*min/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="201.1" spread="275.5"/>
                    <measurement group_id="O2" value="132.2" spread="87.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GIRmin</title>
        <description>Minimal glucose infusion rate (GIRmin) for Xeris vs. Lilly (non-inferiority)</description>
        <time_frame>every 2 minutes for 1 hour post-dose of each glucagon</time_frame>
        <population>13 subjects completed the study following a consistent protocol using the glucagon doses described in the arm/group description. 7 subjects were randomized to get Xeris glucagon first, 6 subjects were randomized to get Lilly glucagon first. All 13 subjects received both glucagon injections, and the data is reported for each drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Xeris Glucagon</title>
            <description>Xeris glucagon 50 micrograms, subcutaneous injection
Xeris glucagon: The subject is given an injection of xeris glucagon</description>
          </group>
          <group group_id="O2">
            <title>Lilly Glucagon</title>
            <description>Lilly glucagon 30 micrograms, subcutaneous injection
Lilly glucagon: The subject is given an injection of lilly glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>GIRmin</title>
          <description>Minimal glucose infusion rate (GIRmin) for Xeris vs. Lilly (non-inferiority)</description>
          <population>13 subjects completed the study following a consistent protocol using the glucagon doses described in the arm/group description. 7 subjects were randomized to get Xeris glucagon first, 6 subjects were randomized to get Lilly glucagon first. All 13 subjects received both glucagon injections, and the data is reported for each drug.</population>
          <units>dextrose mg/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="2.2"/>
                    <measurement group_id="O2" value="2.9" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>t½Max</title>
        <description>Glucagon t½max for Xeris vs. Lilly (non-inferiority)</description>
        <time_frame>every 2 minutes for 1 hour post-dose of each glucagon</time_frame>
        <population>13 subjects completed the study following a consistent protocol using the glucagon doses described in the arm/group description. 7 subjects were randomized to get Xeris glucagon first, 6 subjects were randomized to get Lilly glucagon first. All 13 subjects received both glucagon injections, and the data is reported for each drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Xeris Glucagon</title>
            <description>Xeris glucagon 50 micrograms, subcutaneous injection
Xeris glucagon: The subject is given an injection of xeris glucagon</description>
          </group>
          <group group_id="O2">
            <title>Lilly Glucagon</title>
            <description>Lilly glucagon 30 micrograms, subcutaneous injection
Lilly glucagon: The subject is given an injection of lilly glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>t½Max</title>
          <description>Glucagon t½max for Xeris vs. Lilly (non-inferiority)</description>
          <population>13 subjects completed the study following a consistent protocol using the glucagon doses described in the arm/group description. 7 subjects were randomized to get Xeris glucagon first, 6 subjects were randomized to get Lilly glucagon first. All 13 subjects received both glucagon injections, and the data is reported for each drug.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" spread="3.1"/>
                    <measurement group_id="O2" value="5.9" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Injection Pain</title>
        <description>Quantitation of adverse events related to glucagon injection for Xeris vs. Lilly:
-average Injection pain on a 10 cm standard VAS: 0 = no pain, 10 = worst imaginable pain reported immediately after injection of glucagon</description>
        <time_frame>immediately after injection</time_frame>
        <population>13 subjects completed the study following a consistent protocol using the glucagon doses described in the arm/group description. 7 subjects were randomized to get Xeris glucagon first, 6 subjects were randomized to get Lilly glucagon first. All 13 subjects received both glucagon injections, and the data is reported for each drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Xeris Glucagon</title>
            <description>Xeris glucagon 50 micrograms, subcutaneous injection
Xeris glucagon: The subject is given an injection of xeris glucagon</description>
          </group>
          <group group_id="O2">
            <title>Lilly Glucagon</title>
            <description>Lilly glucagon 30 micrograms, subcutaneous injection
Lilly glucagon: The subject is given an injection of lilly glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Injection Pain</title>
          <description>Quantitation of adverse events related to glucagon injection for Xeris vs. Lilly:
-average Injection pain on a 10 cm standard VAS: 0 = no pain, 10 = worst imaginable pain reported immediately after injection of glucagon</description>
          <population>13 subjects completed the study following a consistent protocol using the glucagon doses described in the arm/group description. 7 subjects were randomized to get Xeris glucagon first, 6 subjects were randomized to get Lilly glucagon first. All 13 subjects received both glucagon injections, and the data is reported for each drug.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" spread="17.7"/>
                    <measurement group_id="O2" value="7.6" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Injection Site Erythema</title>
        <description>Quantitation of adverse events related to glucagon injection for Xeris vs. Lilly:
-Injection site erythema or other local reaction, maximum diameter within 1 hour of injection</description>
        <time_frame>within 1 hour of injection</time_frame>
        <population>13 subjects completed the study following a consistent protocol using the glucagon doses described in the arm/group description. 7 subjects were randomized to get Xeris glucagon first, 6 subjects were randomized to get Lilly glucagon first. All 13 subjects received both glucagon injections, and the data is reported for each drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Xeris Glucagon</title>
            <description>Xeris glucagon 50 micrograms, subcutaneous injection
Xeris glucagon: The subject is given an injection of xeris glucagon</description>
          </group>
          <group group_id="O2">
            <title>Lilly Glucagon</title>
            <description>Lilly glucagon 30 micrograms, subcutaneous injection
Lilly glucagon: The subject is given an injection of lilly glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Injection Site Erythema</title>
          <description>Quantitation of adverse events related to glucagon injection for Xeris vs. Lilly:
-Injection site erythema or other local reaction, maximum diameter within 1 hour of injection</description>
          <population>13 subjects completed the study following a consistent protocol using the glucagon doses described in the arm/group description. 7 subjects were randomized to get Xeris glucagon first, 6 subjects were randomized to get Lilly glucagon first. All 13 subjects received both glucagon injections, and the data is reported for each drug.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximal Nausea</title>
        <description>Quantitation of adverse events related to glucagon injection for Xeris vs. Lilly:
-Maximal nausea within 1 hour of injection on a 10 cm VAS: no nausea = 0, vomiting = 10</description>
        <time_frame>within 1 hour of injection</time_frame>
        <population>13 subjects completed the study following a consistent protocol using the glucagon doses described in the arm/group description. 7 subjects were randomized to get Xeris glucagon first, 6 subjects were randomized to get Lilly glucagon first. All 13 subjects received both glucagon injections, and the data is reported for each drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Xeris Glucagon</title>
            <description>Xeris glucagon 50 micrograms, subcutaneous injection
Xeris glucagon: The subject is given an injection of xeris glucagon</description>
          </group>
          <group group_id="O2">
            <title>Lilly Glucagon</title>
            <description>Lilly glucagon 30 micrograms, subcutaneous injection
Lilly glucagon: The subject is given an injection of lilly glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Maximal Nausea</title>
          <description>Quantitation of adverse events related to glucagon injection for Xeris vs. Lilly:
-Maximal nausea within 1 hour of injection on a 10 cm VAS: no nausea = 0, vomiting = 10</description>
          <population>13 subjects completed the study following a consistent protocol using the glucagon doses described in the arm/group description. 7 subjects were randomized to get Xeris glucagon first, 6 subjects were randomized to get Lilly glucagon first. All 13 subjects received both glucagon injections, and the data is reported for each drug.</population>
          <units>cm</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dermal Response (Draize Scale for Erythema and Eschar Formation)</title>
        <description>Average grade on the erythema and eschar formation portion of the Draize scale for dermal response (0 being the lowest, 4 being the highest)</description>
        <time_frame>within 1 hour of injection</time_frame>
        <population>13 subjects completed the study following a consistent protocol using the glucagon doses described in the arm/group description. 7 subjects were randomized to get Xeris glucagon first, 6 subjects were randomized to get Lilly glucagon first. All 13 subjects received both glucagon injections, and the data is reported for each drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Xeris Glucagon</title>
            <description>Xeris glucagon 50 micrograms, subcutaneous injection
Xeris glucagon: The subject is given an injection of xeris glucagon</description>
          </group>
          <group group_id="O2">
            <title>Lilly Glucagon</title>
            <description>Lilly glucagon 30 micrograms, subcutaneous injection
Lilly glucagon: The subject is given an injection of lilly glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Dermal Response (Draize Scale for Erythema and Eschar Formation)</title>
          <description>Average grade on the erythema and eschar formation portion of the Draize scale for dermal response (0 being the lowest, 4 being the highest)</description>
          <population>13 subjects completed the study following a consistent protocol using the glucagon doses described in the arm/group description. 7 subjects were randomized to get Xeris glucagon first, 6 subjects were randomized to get Lilly glucagon first. All 13 subjects received both glucagon injections, and the data is reported for each drug.</population>
          <units>score on draize scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dermal Response (Draize Scale Grade for Edema Formation)</title>
        <description>Average grade on the edema formation portion of the Draize scale for dermal response (0 being the lowest, 4 being the highest)</description>
        <time_frame>within 1 hour of injection</time_frame>
        <population>13 subjects completed the study following a consistent protocol using the glucagon doses described in the arm/group description. 7 subjects were randomized to get Xeris glucagon first, 6 subjects were randomized to get Lilly glucagon first. All 13 subjects received both glucagon injections, and the data is reported for each drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Xeris Glucagon</title>
            <description>Xeris glucagon 50 micrograms, subcutaneous injection
Xeris glucagon: The subject is given an injection of xeris glucagon</description>
          </group>
          <group group_id="O2">
            <title>Lilly Glucagon</title>
            <description>Lilly glucagon 30 micrograms, subcutaneous injection
Lilly glucagon: The subject is given an injection of lilly glucagon</description>
          </group>
        </group_list>
        <measure>
          <title>Dermal Response (Draize Scale Grade for Edema Formation)</title>
          <description>Average grade on the edema formation portion of the Draize scale for dermal response (0 being the lowest, 4 being the highest)</description>
          <population>13 subjects completed the study following a consistent protocol using the glucagon doses described in the arm/group description. 7 subjects were randomized to get Xeris glucagon first, 6 subjects were randomized to get Lilly glucagon first. All 13 subjects received both glucagon injections, and the data is reported for each drug.</population>
          <units>score on draize scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 day</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Xeris Glucagon</title>
          <description>Xeris glucagon 50 micrograms, subcutaneous injection
Xeris glucagon: The subject is given an injection of xeris glucagon</description>
        </group>
        <group group_id="E2">
          <title>Lilly Glucagon</title>
          <description>Lilly glucagon 30 micrograms, subcutaneous injection
Lilly glucagon: The subject is given an injection of lilly glucagon</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Courtney Balliro, BS, RN, CDE</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-726-1242</phone>
      <email>cballiro@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

